Spedra

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

avanafil

Available from:

Menarini International Operations Luxembourg S.A.

ATC code:

G04BE10

INN (International Name):

avanafil

Therapeutic group:

Zdravila, ki se uporabljajo pri erektilni disfunkciji

Therapeutic area:

Erektilna disfunkcija

Therapeutic indications:

Zdravljenje erektilne disfunkcije pri odraslih moških. Da bi Spedra, da bo učinkovito, spolne stimulacije je potrebno.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2013-06-21

Patient Information leaflet

                                46
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare, L-1611Luxembourg
Luksemburg
12.
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z
ZDRAVILOM
EU/1/13/841/001 4x1 tableta
EU/1/13/841/002 8x1 tableta
EU/1/13/841/003 12x1 tableta
EU/1/13/841/012 4x1 tableta
EU/1/13/841/013 8x1 tableta
EU/1/13/841/014 12x1 tableta
13.
ŠTEVILKA SERIJE
Serija
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Spedra 50 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
47
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT
1.
IME ZDRAVILA
_ _
Spedra 50 mg tablete
avanafil
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Menarini Luxembourg
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do:
4.
ŠTEVILKA SERIJE
Serija
5.
DRUGI PODATKI
48
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA
1.
IME ZDRAVILA
Spedra 100 mg tablete
avanafil
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena tableta vsebuje 100 mg avanafila.
3.
SEZNAM POMOŢNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
2x1 tableta
4x1 tableta
8x1 tableta
12x1 tableta
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
49
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Menarini International Operations Luxembourg S.A.
1, Avenue de la Gare, L-161
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Spedra 50 mg tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta vsebuje 50 mg avanafila.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
tableta
Bledo rumene ovalne tablete z vtisnjeno oznako “50” na eni strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravljenje erektilne disfunkcije pri odraslih moških.
Zdravilo Spedra je učinkovito le ob spolnem vzburjenju.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Uporaba pri odraslih moških _
Priporočeni odmerek je 100 mg, ki se ga jemlje po potrebi približno
15 do 30 minut pred spolnim
odnosom (glejte poglavje 5.1). Glede na učinkovitost in prenašanje
zdravila pri posamezniku se lahko
odmerek poveča na največ 200 mg ali zmanjša na 50 mg. Največja
priporočena pogostnost odmerjanja
je enkrat na dan. Za odziv na zdravljenje je potrebno spolno
vzburjenje.
_Posebne skupine bolnikov _
_Starejši (stari ≥ 65 let) _
Pri starejših bolnikih odmerka ni treba prilagajati. Za starejše
bolnike, ki so stari 70 let in več, so
podatki omejeni.
_Okvara ledvic _
Pri bolnikih z blago do zmerno okvaro ledvic (očistek kreatinina ≥
30 ml/min) odmerka ni treba
prilagajati. Zdravilo Spedra je kontraindicirano pri bolnikih s hudo
okvaro ledvic (očistek kreatinina
< 30 ml/min) (glejte poglavji 4.3 in 5.2). Pri bolnikih z blago do
zmerno okvaro ledvic (očistek
kreatinina ≥ 30 ml/min, vendar <80 ml/min), ki so bili vključeni v
študije tretje faze, so opazili
zmanjšano učinkovitost v primerjavi z bolniki z normalno ledvično
funkcijo.
_Okvara jeter _
Zdravilo Spedra je kontraindicirano pri bolnikih s hudo okvaro jeter
(razred C po Child-Pughu) (glejte
poglavji 4.3 in 5.2). Pri bolnikih z blago do zmerno okvaro jeter
(razred A ali B po Child-Pughu) je
treba zdravljenje začeti z najnižjim učinkovitim odmerkom in
prilagoditi odmerjanje glede na
toleranco.
_Uporaba pri moških s sladkorno boleznijo _
3
Pri moških s sladkorno boleznijo odmerka ni treba prilag
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-11-2021
Public Assessment Report Public Assessment Report Bulgarian 10-03-2015
Patient Information leaflet Patient Information leaflet Spanish 24-11-2021
Public Assessment Report Public Assessment Report Spanish 10-03-2015
Patient Information leaflet Patient Information leaflet Czech 24-11-2021
Public Assessment Report Public Assessment Report Czech 10-03-2015
Patient Information leaflet Patient Information leaflet Danish 24-11-2021
Public Assessment Report Public Assessment Report Danish 10-03-2015
Patient Information leaflet Patient Information leaflet German 24-11-2021
Public Assessment Report Public Assessment Report German 10-03-2015
Patient Information leaflet Patient Information leaflet Estonian 24-11-2021
Public Assessment Report Public Assessment Report Estonian 10-03-2015
Patient Information leaflet Patient Information leaflet Greek 24-11-2021
Public Assessment Report Public Assessment Report Greek 10-03-2015
Patient Information leaflet Patient Information leaflet English 24-11-2021
Public Assessment Report Public Assessment Report English 10-03-2015
Patient Information leaflet Patient Information leaflet French 24-11-2021
Public Assessment Report Public Assessment Report French 10-03-2015
Patient Information leaflet Patient Information leaflet Italian 24-11-2021
Public Assessment Report Public Assessment Report Italian 10-03-2015
Patient Information leaflet Patient Information leaflet Latvian 24-11-2021
Public Assessment Report Public Assessment Report Latvian 10-03-2015
Patient Information leaflet Patient Information leaflet Lithuanian 24-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-11-2021
Public Assessment Report Public Assessment Report Lithuanian 10-03-2015
Patient Information leaflet Patient Information leaflet Hungarian 24-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 24-11-2021
Public Assessment Report Public Assessment Report Hungarian 10-03-2015
Patient Information leaflet Patient Information leaflet Maltese 24-11-2021
Public Assessment Report Public Assessment Report Maltese 10-03-2015
Patient Information leaflet Patient Information leaflet Dutch 24-11-2021
Public Assessment Report Public Assessment Report Dutch 10-03-2015
Patient Information leaflet Patient Information leaflet Polish 24-11-2021
Public Assessment Report Public Assessment Report Polish 10-03-2015
Patient Information leaflet Patient Information leaflet Portuguese 24-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 24-11-2021
Public Assessment Report Public Assessment Report Portuguese 10-03-2015
Patient Information leaflet Patient Information leaflet Romanian 24-11-2021
Public Assessment Report Public Assessment Report Romanian 10-03-2015
Patient Information leaflet Patient Information leaflet Slovak 24-11-2021
Public Assessment Report Public Assessment Report Slovak 10-03-2015
Patient Information leaflet Patient Information leaflet Finnish 24-11-2021
Public Assessment Report Public Assessment Report Finnish 10-03-2015
Patient Information leaflet Patient Information leaflet Swedish 24-11-2021
Public Assessment Report Public Assessment Report Swedish 10-03-2015
Patient Information leaflet Patient Information leaflet Norwegian 24-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 24-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 24-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 24-11-2021
Patient Information leaflet Patient Information leaflet Croatian 24-11-2021
Public Assessment Report Public Assessment Report Croatian 10-03-2015

Search alerts related to this product

View documents history